Title : Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.

Pub. Date : 2012 Feb

PMID : 22239497






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Recent evidence points to a beneficial role of recombinant erythropoietin (EPO) in alleviating ribavirin-induced anaemia thereby improving quality of life, enabling higher ribavirin dosage and consequently improving SVR. Ribavirin erythropoietin Homo sapiens
2 Recent evidence points to a beneficial role of recombinant erythropoietin (EPO) in alleviating ribavirin-induced anaemia thereby improving quality of life, enabling higher ribavirin dosage and consequently improving SVR. Ribavirin erythropoietin Homo sapiens
3 Recent evidence points to a beneficial role of recombinant erythropoietin (EPO) in alleviating ribavirin-induced anaemia thereby improving quality of life, enabling higher ribavirin dosage and consequently improving SVR. Ribavirin erythropoietin Homo sapiens
4 Recent evidence points to a beneficial role of recombinant erythropoietin (EPO) in alleviating ribavirin-induced anaemia thereby improving quality of life, enabling higher ribavirin dosage and consequently improving SVR. Ribavirin erythropoietin Homo sapiens
5 A consensus was reached recommending the use of EPO for patients infected with viral genotype 1 developing significant anaemia below 100 g/L haemoglobin and a haematocrit of <30% during standard therapy to improve quality of life and sustain optimal ribavirin dose. Ribavirin erythropoietin Homo sapiens